Neoprobe Lymphoseek trial progresses

AuntMinnie.com staff writers

Jun 20, 2007

Gamma camera probe developer Neoprobe said that a multicenter phase II clinical study of its Lymphoseek radioactive targeting agent has yielded positive preliminary results.

In the trial, localization of Lymphoseek to lymphoid tissue was observed in over 94% of the sentinel lymph node biopsy (SNLB) procedures performed in patients with either breast cancer or melanoma, according to the Dublin, OH-based firm. Neoprobe said it's now preparing to submit its phase III clinical trial protocol to the U.S. Food and Drug Administration (FDA).

By AuntMinnie.com staff writers
June 21, 2007

Related Reading

Neoprobe's Q1 sales slip, loss edges up, May 1, 2007

Neoprobe Lymphoseek trial moves forward, March 5, 2007

Neoprobe gets FDA nod for more Lymphoseek trials, January 17, 2007

Neoprobe debuts Bluetooth probe, October 10, 2006

Neoprobe, Estech ink distribution deal, September 11, 2006

Copyright © 2007 AuntMinnie.com

2024 10 28 Meningioma Thumbnail

Intraarterial PRRT safe in patients with meningioma

October 28, 2024

NNSA's Mo-99 program: A bumpy ride

October 10, 2024

Theranostics for neuroendocrine tumors: Glenda’s journey

Theranostics for neuroendocrine tumors: Glenda’s journey

December 1, 2024

Lesion uptake from a patient with a solitary fibrous tumor and its FAP expression on gallium-68 (GA-68)-FAPI-46 (A) and intratherpeutic Y-90-FAPI-46 (B). The panel shows the constructed time activity curve with the three PET/CT measurements.

SNMMI: PET-based protocol shows promise in radioligand therapy

June 12, 2024

Intraarterial PRRT safe in patients with meningioma

Intraarterial peptide receptor radionuclide therapy (PRRT) is a safe and effective alternative to intravenous PRRT in patients with advanced meningioma.

October 28, 2024

2024 10 28 Meningioma Thumbnail

NNSA's Mo-99 program: A bumpy ride

Last year was a bumpy ride for a U.S. initiative to secure domestic supplies of molybdenum-99 (Mo-99).

October 10, 2024

How effective is Pluvicto in a ‘real-world’ setting?

Pluvicto appears to perform as effectively in prostate cancer patients in “real-world” settings as it did in clinical trials prior to its approval.

September 20, 2024

SNMMI: PET-based protocol shows promise in radioligand therapy

By Amerigo Allegretto

A PET-based scout dosimetry protocol can be feasible in treating lesions with yttrium-90 FAPI (Y-90 FAPI) radioligand therapy.

June 12, 2024

Lesion uptake from a patient with a solitary fibrous tumor and its FAP expression on gallium-68 (GA-68)-FAPI-46 (A) and intratherpeutic Y-90-FAPI-46 (B). The panel shows the constructed time activity curve with the three PET/CT measurements.

The rise of theranostics: Part 3 -- What is a theranostics center?

For this third in a series covering the rise of theranostics, AuntMinnie.com asked four doctors of theranostics to discuss the spectrum of freestanding theranostics center development.

June 3, 2024

Part3 Riseof Thernaostics Cover

Can AI improve sustainability in nuclear medicine?

Nuclear medicine experts support the use of AI to improve sustainability of practices in the field, yet say implementation will require careful consideration of the technology’s benefits and detriments.

April 9, 2024

ChatGPT powered by GPT-4 and using DALL-E−3 was asked to generate an image for teaching purposes that demonstrated: a nuclear medicine bone scan with skeletal metastases (top left); coronary artery disease (top right); an F-18 FDG-PET scan of the brain with Alzheimer's disease (bottom left); and an x-ray showing a fracture (bottom right). These are misleading for educational purposes and for patients who may be searching for information. Image and caption courtesy of Radiography.

The rise of theranostics: Part 2 -- Moving into communities

In part 2 of The Rise of theranostics series, experts weigh in on getting started in prostate cancer theranostics as some private urology, radiation oncology practices, and radiologist groups begin building their abilities.

April 4, 2024

Theranostics with Thomas Hope, MD, University of California, San Francisco (UCSF)

SNMMI to tackle Capitol Hill

By AuntMinnie.com staff writers

The Society of Nuclear Medicine and Molecular Imaging (SNMMI) will host its annual Hill Day on April 5 in Washington, DC.

April 3, 2024

The rise of theranostics: Part 1 -- Gaining momentum

FDA-approved radiopharmaceuticals have energized the field of theranostics. In part 1 of a series, experienced theranostics leaders offer implications of the latest clinical trials, how a theranostics clinic works, and advice for introducing theranostics.

March 19, 2024

Team members from the theranostics clinic under University of Texas Health Science Center at San Antonio's Department of Radiology show one aspect of a Pluvicto infusion treatment. The L block lead shield over the syringe helps protect certified nuclear medicine technologist James Johnson (left), and nuclear radiologist Penny Vroman, MD (right), from radiation emitted by the drug. (Photo courtesy of UT Health San Antonio Department of Radiology)

Cannabis may influence bowel motility

Physicians, health care providers, and medical staff caring for patients who use cannabis should be familiar with the effects of the drug on gut motility, a recent report advises.

March 11, 2024

Hold off on the Egg McMuffins before GES tests, experts say

Nuclear medicine technologists are being advised that not just any meal works for patients before gastric emptying scintigraphy (GES).

March 7, 2024

Neiman HPI publishes advanced imaging prediction index

By Kate Madden Yee

The Harvey L. Neiman Health Policy Institute (HPI) has developed and released a comorbidity index designed to help predict use of advanced imaging.

January 25, 2024

2018 08 14 19 14 9213 Neiman Hip 400

Page 1 of 436